- Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients
- Treatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung Disease
- Epetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union
Barrington Research Maintains Outperform on Perficient, Lowers Price Target to $80
Barrington Research analyst Vincent Colicchio maintains Perficient (NASDAQ:PRFT) with a Outperform and lowers the price target from $110 to $80.
